Kaydan Wealth Management Inc. Sells 910 Shares of Pfizer Inc. (NYSE:PFE)

Kaydan Wealth Management Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 6.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,283 shares of the biopharmaceutical company’s stock after selling 910 shares during the period. Kaydan Wealth Management Inc.’s holdings in Pfizer were worth $396,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PFE. Advisor OS LLC raised its stake in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC boosted its position in Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares in the last quarter. Lantz Financial LLC grew its holdings in shares of Pfizer by 1.3% during the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 381 shares during the period. King Wealth Management Group raised its position in shares of Pfizer by 2.4% in the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. lifted its stake in shares of Pfizer by 4.0% in the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 391 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock traded up $0.62 during trading on Monday, reaching $28.36. The stock had a trading volume of 35,378,817 shares, compared to its average volume of 41,267,238. The firm has a market cap of $160.68 billion, a PE ratio of -472.58, a PEG ratio of 1.09 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average is $27.72 and its two-hundred day moving average is $27.70. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the business posted $1.23 earnings per share. The company’s revenue was down 19.5% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.92%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, June 17th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.